GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

Mississauga, Ontario Tuesday, May 27, 2025, 16:00 Hrs [IST] ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

Two of the treatments that will be receiving plenty of attention in GSK’s presentations are mepolizumab and depemokimab, which are both monoclonal antibodies (mAbs) that target IL-5, a key cytokine or ...

Journalists and news professionals across Canada today are launching an industry-wide mental health support program to combat stress, burnout and trauma exposure. Twenty volunteers were trained this ...

Despite its profile as a long-acting IL-5 receptor antagonist with convenient semiannual dosing, GSK's depemokimab, the most advanced asthma pipeline asset, has generated relatively limited ...